> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Abbott Cardiac Arrhythmia Mapping Platform Cleared
- URL: https://www.fdaweb.com/abbott-cardiac-arrhythmia-mapping-platform-cleared/
- Published: 2022-01-12T12:00:00.000Z
- Updated: 2026-09-14T17:28:17.000Z
- Author: David McFarland
- Tags: Devices, #legacy-id-D5150915

FDA has cleared an Abbott 510(k) for the EnSite EP System with EnSite Omnipolar Technology (OT), a new cardiac mapping platform designed to help physicians better treat cardiac arrhythmias. The device creates “highly detailed” three-dimensional maps of the heart to help physicians identify and then treat areas of the heart where abnormal rhythms originate, the company says.

It uses Abbott’s proprietary EnSite OT, which “leverages the Advisor HD Grid Catheter to provide true electrograms (EGMs) regardless of how the catheter is oriented within the heart,” according to the company. “With the ability to sample EGMs in 360 degrees, the EnSite X EP System with EnSite OT can map 1 million points in the heart and provide more precise location of treatment areas.”